- Sort by Product ID
- Display 15 Products per page
Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: April 1, 2008 | Price: $995.00 – $7,990.00
Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...Published: March 15, 2008 | Price: $6,995.00 – $13,990.00
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: June 1, 2007 | Price: $500.00 – $5,990.00
Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. Kalorama Information's: Multiple Sclerosis Treatments: World Market Outlook to 2011 is one of the few publications to take a detailed look at multiple sclerosis treatment market worldwide, as well as treatments that...Published: July 1, 2007 | Price: $5,995.00 – $11,990.00
This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic...Published: April 1, 2007 | Price: $1,295.00 – $2,995.00
SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban currently holds a tenuous lock on, is about to change, with a major new brand ready to shake up the current market share. At the...Published: April 1, 2007 | Price: $2,995.00 – $5,990.00
The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends: Drug resistance and Interactions Antibiotic Abuse Antibiotic Cycling Addressing Market Trends Antibiotic...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...